Health-related quality of life in colorectal cancer patients

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 493-504

  Conroy, Thierry ^a   Blazeby, Jane M ^b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer; Health outcome measures; Quality of life; Survivors

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; CISPLATIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; HYDRAZINE DERIVATIVE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; RALTITREXED; UFT;

CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DIARRHEA; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; NAUSEA AND VOMITING; ONCOLOGY; ORGANIZATION; PATIENT COMPLIANCE; PHYSICIAN; QUALITY OF LIFE; REVIEW; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 0041509040     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.493     Document Type: Review

References (95)

1. World Health Organization. International Agency for Research on Cancer. World Cancer Report. Stewart BW, Kleihues P (Eds), International Agency for Research on Cancer, Lyon, France (2003).
2. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Br. Med. J. 321 (7260), 531-536 (2000).
3. Kjeldsen BJ, Thorsen H, Whalley D, Kronborg O. Influence of follow-up on health-related quality of life after radical surgery for colorectal cancer. Scand. J. Gastroenterol. 34(5), 509-515 (1999).
4. Camilleri-Brennan J, Ruta DA, Steele RJ. Patient Generated Index: new instrument for measuring quality of life in patients with rectal cancer. World J. Surg. 26(11), 1354-1359 (2002).
5. Spitzer WO, Dobson AJ, Hall J et al. Measuring the quality of life of cancer patients. A concise QL-index for use by physicians. J. Chron. Dis. 34(12), 585-597 (1981).
6. Sloan JA, Loprinzi CL, Kuross SA et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J. Clin. Oncol. 16(11), 3662-3673 (1998).
7. Zieren HU, Jacobi CA, Zieren J, Müler JM. Lebensqualitätserfassung nach resektion colorectaler carcinome. Chirurg 67(7), 703-709 (1996).
8. Schipper H, Clinch J, McMurray A, Lewitt M. Measuring the quality of life of cancer patients: the Functional Living Index - Cancer: development and validation. J. Clin. Oncol. 2(5), 472-483 (1984).
9. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a Quality-of-Life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85 (5), 365-376 (1993).
10. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient-assessed health outcome measures. Br. Med. J. 324(7351), 1417 (2002).
11. Apolone G, Filiberti A, Cifani R, Ruggiata R, Mosconi P. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann. Oncol. 9(5), 549-557 (1998).
12. Seymour MT, Tabah-Fisch I, Homerin M. Quality of Life (HRQoL) in advanced colorectal cancer (ACC): a comparison of HRQoL during bolus plus infusion 5FU/leucovorin (LV5FU2) with or without oxaliplatin. Proc. Am. Soc. Clin. Oncol. 18, 234a (1999) (Abstract 901).
13. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16(1), 139-144 (1998).
14. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J. Clin. Oncol. 11 (3), 570-579 (1993).
15. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual. Life Res. 11 (3), 207-221 (2002).
16. De Haes JCJM, Van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br. J. Cancer 62(6), 1034-1038 (1990).
17. Zigmond AS, Snaith RP.The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 67(6), 361-370 (1983).
18. Bosset JF, Schraub S, Pelissier E et al. Proposition of a specific quality of life scale for patients treated by conservative surgery for rectal cancer. Lyon Chir. 89(1), 135 (1993) (Abstract).
19. Padilla GV, Grant MM. Quality of life as a cancer nursing outcome variable. ANS Adv. Nurs. Sci. 8(1), 45-60 (1985).
20. Sprangers MAG, te Velde A, Aaronson NK The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). Eur. J. Cancer 35(2), 238-247 (1999).
21. Wils J, Sahmoud T, Sobrero A et al. Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. Tumori 84(3), 335-347 (1998).
22. Kavadas V, Blazeby JM, Conroy T et al. Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastases from colorectal cancer. Eur. J. Cancer 39(6), 1259-1263 (2003).
23. Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy - Colorectal (FACT-C) quality of life instrument. Qual. Life Res. 8(3), 181-195 (1999).
24. Revicki DA, Osoba D, Fairclough D et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual. Life Res. 9(8), 887-900 (2000).
25. Sprangers MA, Taal BG, Aaronson NK, te Velde A. Quality of life in colorectal cancer. Stoma vs. nonstoma patients. Dis. Colon Rectum 38(4), 361-369 (1995).
26. Sprangers MAG, te Velde A, Aaronson NK, Taal BG. Quality of Life following surgery for colorectal cancer: a literature review. Psychooncology 2(4), 247-259 (1993).
27. Camilleri-Brennan J, Steele RJC. Quality of life after treatment for rectal cancer. Br. J. Surg. 85(8), 1036-1043 (1998).
28. Kuzu MA, Topcu O, Ucar K et al. Effect of sphincter-sacrificing surgery for rectal carcinoma on quality of life in Muslim patients. Dis. Colon Rectum 45(10), 1359-1366 (2002)
29. O'Leary DP, Fide CJ, Foy C, Lucarotti ME. Quality of life after low anterior resection with total mesorectal excision and temporary loop ileostomy for rectal carcinoma. Br. J. Surg. 88(9), 1216-1220 (2001).
30. Grumann MM, Noack EM, Hoffmann IA, Schlag PM. Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann. Surg. 233(2), 149-156 (2001).
31. Allal AS, Bieri S, Pelloni A et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes. Br. J. Cancer 82(6), 1131-1137 (2000).
32. Pocard M, Zinzindohoue F, Haab F, Caplin S, Parc R, Tiret E. A prospective study of sexual and urinary function before and after total mesorectal excision with autonomic nerve preservation for rectal cancer. Surgery 131(4), 368-372 (2002).
33. Mannaerts GH, Rutten HJT, Martjin H, Hanssens PEJ, Wiggers T. Effects on functional outcome after IORT-containing multimodality treatment for locally advanced primary and locally recurrent rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 54(4), 1082-1088 (2002).
34. Shibata D, Guillem JG, Lanouette N et al. Functional and quality-of-life outcomes in patients with rectal cancer after combined modality therapy, intraoperative radiation therapy and sphincter preservation. Dis. Colon Rectum 43(6), 752-758 (2000).
35. Camilleri-Brennan J, Steele RJC. Prospective analysis of quality of life and survival following mesorectal excision for rectal cancer. Br. J. Surg. 88(12), 1617-1622 (2001).
36. Guren MG, Wiig JN, Dueland S et al. Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer. Eur. J. Surg. Oncol. 27(7), 645-651 (2001).
37. Rockwood TH, Church JM, Fleshman JW et al. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis. Colon Rectum 43(1), 9-16 (2000).
38. Furst A, Burghofer K, Hutzel L, Jauch KW. Neorectal reservoir is not the functional principle of the colonic J- pouch: the volume of a short colonic J-pouch does not differ from a straight coloanal anastomosis. Dis. Colon Rectum 45(5), 660-667 (2002).
39. Hallbook O, Hass U, Wanstrom A, Sjodahl R. Quality of life measurement after rectal excision for cancer. Comparison between straight and colonic J-pouch anastomosis. Scand. J. Gastroenterol. 32(5), 490-493 (1997).
40. Sailer M, Fuchs KH, Fein M, Thiede A. Randomized clinical trial comparing quality of life after straight and pouch coloanal reconstruction. Br. J. Surg. 89(9), 1108-1117 (2002).
41. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy versus open colectomy for colon cancer: a randomized trial. JAMA 287(3), 321-328 (2002).
42. Schwenk W, Bohm B, Muller JM. Postoperative pain and fatigue after laparoscopic or conventional colorectal resections. A prospective randomized trial. Surg. Endosc. 12(9), 1131-1136 (1998).
43. Guren MG, Dueland S, Skovlund E, Fossa SD, Poulsen JP, Tveit KM. Quality of life during radiotherapy for rectal cancer. Eur. J. Cancer 39(5), 587-594 (2003).
44. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann. Oncol. 8(1), 65-70 (1997).
45. Zaniboni A, Labianca R, Marsoni S et al. GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma: long-term results and evaluation of the indicators of health-related quality of life. Cancer 82(11), 2135-2144 (1998).
46. Bernhard J, Hurny C, Maibach R, Herrmann R, Laffer U. Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Ann. Oncol. 10(7), 775-782 (1999).
47. Gray R, Watson M, McConkey C et al. Adjuvant chemotherapy for colorectal cancer has only minor impact on patient reported quality of life: a study of 785 patients randomized in the UKCCCR QUASAR trial. Proc. Am. Soc. Clin. Oncol. 20(Pt 1), 407a (2001) (Abstract 1623).
48. Stiggelbout AM, De Haes JC, Vree R et al. Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up. Br. J. Cancer 75 (6), 914-920 (1997).
49. Schag CAC, Ganz PA, Wing DS, Sim MS, Lee JJ. Quality of life in adult survivors of lung, colon and prostate cancer. Qual. Life Res. 3(2), 127-141 (1994).
50. Ramsey SD, Andersen MR, Etzioni R et al. Quality of life in survivors of colorectal carcinoma. Cancer 88(6), 1294-1303 (2000).
51. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long-term survivors of colorectal cancer. Am. J. Gastroenterol. 97(5), 12218-1234 (2002).
52. Mosconi P, Apolone G, Barni S, Secondino S, Sbanotto A, Filiberti A. Quality of life in breast and colon cancer long-term survivors: an assessment with the EORTC QLQ-C30 and SF-36 questionnaires. Tumori 88(2), 110-116 (2002).
53. Hamashima C. Long-term quality of life of postoperative rectal cancer patients. J. Gastroenterol. Hepatol. 17(5), 571-576 (2002).
54. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J. Clin. Oncol. 14(3), 671-679 (1996).
55. Sullivan BA, McKinnis R, Laufman L. Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: a randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorin. Pharmacotherapy 15(5), 600-607 (1995).
56. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life and survival in patients with colorectal liver metastases. J. Clin. Oncol. 14(1), 171-175 (1996).
57. Hilgenfeld RU, Mansmann U, Guggenmoos-Holzmann I, Thiel E, Kreuser ED. Quality of life (QL) is a prognostic factor (PF) for survival in patients with advanced colorectal cancer (CRC). Eur. J. Cancer 33(Suppl. 8), S170 (1997) (Abstract 760).
58. Mormont MC, Waterhouse J, Bleuzen P et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 6(8), 3038-3045 (2000).
59. Maughan TS, James RD, Kerr DJ et al. Comparison of survival, palliation and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359(9317), 1555-1563 (2002).
60. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur. J. Cancer 38(10), 1351-1357 (2002).
61. Glimelius B, Graf W, Hoffman K, Pahlman L, Sjödén PO, Wennberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. Acta Oncol. 31(6), 645-651 (1992).
62. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjöden PO for the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 73(3), 556-562 (1994).
63. Cunningham D, Zalcberg JR, Rath U et al. Final results ofa randomised trial comparing Tomudex® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol. 7(9), 961-965(1996).
64. Camilleri-Brennan J, Steele RJC. The impact of recurrent rectal cancer on quality of life. Eur. J. Surg. Oncol. 27(4), 349-353 (2001).
65. Esnaola NF, Cantor SB, Johnson ML et al. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J. Clin. Oncol. 20(21), 4361-4367 (2002).
66. Scheithauer W, Rosen H, Kornek G-V, Sebesta C, Depisch D. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br. Med. J. 306(6880), 752-755 (1993).
67. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 344(8932), 1255-1260 (1994).
68. Gray B, Van Hazel G, Hope M et al. Randomised trial of SIR-Spheres® & plus chemotherapy vs. chemotherapy alone or treating patients with liver metastases from primary large bowel cancer. Ann. Oncol. 12(12), 1711-1720 (2001).
69. Allen-Mersh TG, Glover C, Fordy C, Mathur P, Quinn H. Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. Eur. J. Surg. Oncol. 26(5), 468-473 (2000).
70. Kerr DJ, McArdle CS, Ledermann J et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361(9355), 368-373 (2003).
71. Hobday TJ, Kugler JW, Mahoney MR et al. Efficacy and quality-of-life data are related in a Phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J. Clin. Oncol. 20(23), 4574-4580 (2002).
72. Seymour MT, Slevin ML, Kerr DJ et al. Randomized trial assessing the addition of interferon-α2a to fluorouracil and leucovorin in advanced colorectal cancer. J. Clin. Oncol. 14(8), 2280-2288 (1996).
73. Glimelius B, Hoffman K, Olafsdottir M, Pahlman L, Sjöden PO, Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens. Eur. J. Cancer Clin. Oncol. 25(5), 829-835 (1989).
74. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000).
75. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15(1), 110-115 (1997).
76. Douillard JY, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20(17), 3605-3616 (2002).
77. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20(17), 3617-3627 (2002).
78. Borras JM, Sanchez-Hernandez A, Navarro M et al. Compliance, satisfaction and quality of life of patients with colorectal cancer receiving home chemotherapy or out-patient treatment: a randomised controlled trial. Br. Med. J. 322(7290), 826 (2001).
79. Schöffski P, Köhne CH, Schellenberger U et al. Does effective chemotherapy metastatic colorectal cancer (CC) improve quality of life (QL). Preliminary results of a randomized Phase II-study using the EORTC QLQ C30. Eur. J. Cancer 31A(Suppl. 5), S62 (1995) (Abstract 284).
80. Topham C, Moore J. Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer: a pilot study. Eur. J. Cancer Care 6(4), 291-294 (1997).
81. Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann. Oncol. 8(10), 995-1001 (1997).
82. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 355(9209), 1041-1047 (2000).
83. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343(13), 905-914 (2000).
84. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361(9356), 457-464 (2003).
85. Loprinzi CL, Kuross SA, O'Fallon JR et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J. Clin. Oncol. 12(6), 1121-1125 (1994).
86. Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138), 1413-1418 (1998).
87. Michael M, Hedley D, Oza A et al. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a multicenter Canadian trial. Clin. Colorectal Cancer 2 (2), 93-101 (2002).
88. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138), 1407-1412 (1998).
89. Henry B, Becouarn Y, Aussage P. Clinical benefits of stabilisation with second-line chemotherapy in patients with metastatic colorectal cancer. Crit. Rev. Oncol. Hematol. 32(2), 145-154 (1999).
90. Fuchs, CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21(5), 807-814 (2003).
91. Bernhard J, Gelber RD. Workshop on missing data in quality of life research in cancer trials: practical and methodological issues. Stat. Med. 17(5-7), 511-796 (1998).
92. Cocconi G, Cunningham D, Van Cutsem E et al. Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 16(9), 2943-2952 (1998).
93. Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J. Clin. Epidemiol. 53(5), 451-458 (2000).
94. Bottomley A, Vanvoorden V, Flechtner H, Therasse P. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur. J. Cancer 39(3), 275-285 (2003).
95. McLachlan SA, Allenby A, Matthews J et al. Randomized trial of co-ordinated psychosocial interventions based on self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. J. Clin. Oncol. 19 (21), 4117-4125 (2001).